scholarly journals Synergistic antitumor effects of liposomal honokiol combined with cisplatin in colon cancer models

2011 ◽  
Author(s):  
Tian Xia
Keyword(s):  
Colon Cancer ◽  
Antitumor Effects ◽  
Cancer Models

Inulin Coated Mn3O4 Nanocuboids Coupled with RNA Interference Reverse Intestinal Tumorigenesis in Apc Knockout Murine Colon Cancer Models

2021 ◽  
pp. 102504
Author(s):  
Khushboo Kourani ◽  
Poonam Jain ◽  
Aviral Kumar ◽  
Ashok Kumar Jangid ◽  
Guruprasadh Swaminathan ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Rna Interference ◽  
Intestinal Tumorigenesis ◽  
Cancer Models ◽  
Murine Colon

scholarly journals Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models

2018 ◽  
Vol Volume 11 ◽  
pp. 5133-5142 ◽  
Author(s):  
Xibing Zhuang ◽  
Tiankui Qiao ◽  
Sujuan Yuan ◽  
Qi Zhang ◽  
Wei Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lewis Lung ◽  
Lewis Lung Cancer ◽  
Antitumor Effects ◽  
Cancer Models

scholarly journals Antitumor Effects of Systemically Delivered Adenovirus Harboring Trans-Splicing Ribozyme in Intrahepatic Colon Cancer Mouse Model

2008 ◽  
Vol 14 (1) ◽  
pp. 281-290 ◽  
Author(s):  
J.-S. Jeong ◽  
S.-W. Lee ◽  
S.-H. Hong ◽  
Y.-J. Lee ◽  
H.-I. Jung ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Mouse Model ◽  
Antitumor Effects ◽  
Trans Splicing

Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models

2008 ◽  
Vol 22 (8) ◽  
pp. 1125-1132 ◽  
Author(s):  
Wenli Hou ◽  
Lijuan Chen ◽  
Guangli Yang ◽  
Hang Zhou ◽  
Qiqi Jiang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Antitumor Effects ◽  
Cancer Models

scholarly journals Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models

2009 ◽  
Vol 16 (2) ◽  
pp. 401-413 ◽  
Author(s):  
Claudio Festuccia ◽  
Giovanni Luca Gravina ◽  
Anna Maria D'Alessandro ◽  
Paola Muzi ◽  
Danilo Millimaggi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Synergistic Effects ◽  
Disease Stage ◽  
Growth Delay ◽  
Complete Regression ◽  
Antitumor Effects ◽  
Aggressive Prostate Cancer ◽  
Cancer Models ◽  
Hormone Refractory

One of the major obstacles in the treatment of hormone-refractory prostate cancer (HRPC) is the development of chemoresistant tumors. The aim of this study is to evaluate the role of azacitidine as chemosensitizing agent in association with docetaxel (DTX) and cisplatin using two models of aggressive prostate cancer, the 22rv1, and PC3 cell lines. Azacitidine shows antiproliferative effects associated with increased proportion of cells in G0/G1 and evident apoptosis in 22rv1 cells and increased proportion of cells in G2/M phase with the absence of acute cell killing in PC3 cells. In vivo, azacitidine (0.8 mg/kg i.p.) reduced tumor proliferation and induced apoptosis in both xenografts upmodulating the expression of p16INKA, Bax, Bak, p21/WAF1, and p27/KIP1, and inhibiting the activation of Akt activity and the expression of cyclin D1, Bcl-2, and Bcl-XL. In vitro treatments with azacitidine lead to upregulation of cleaved caspase 3 and PARP. BCl2 antagonists, such as HA-14-1, enhanced the effects of azacitidine in these two prostate cancer models. In addition, azacitidine showed synergistic effects with both DTX and cisplatin. In vivo this agent caused tumor growth delay without complete regression in xenograft systems. Azacitidine sensitized PC3 and 22rv1 xenografts to DTX and cisplatin treatments. These combinations were also tolerable in mice and superior to either agent alone. As DTX is the standard first-line chemotherapy for HRPC, the development of DTX-based combination therapies is of great interest in this disease stage. Our results provide a rationale for clinical trials on combination treatments with azacitidine in patients with hormone-refractory and chemoresistant prostate tumors.

Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models

2019 ◽  
Vol 160 ◽  
pp. 110-120 ◽  
Author(s):  
Hye Yeon Jang ◽  
Do Hyung Kim ◽  
Haeng Jung Lee ◽  
Won Dong Kim ◽  
Seog-Young Kim ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Synergistic Effects ◽  
Cancer Models ◽  
Braf Mutant

scholarly journals Evaluation of the antitumor effects of PP242 in a colon cancer xenograft mouse model using comprehensive metabolomics and lipidomics

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Md Mamunur Rashid ◽  
Hyunbeom Lee ◽  
Byung Hwa Jung
Keyword(s):  
Colon Cancer ◽  
Mouse Model ◽  
High Performance ◽  
Tca Cycle ◽  
Treated Group ◽  
Metabolic Changes ◽  
Antitumor Effects ◽  
Xenograft Mouse Model ◽  
Metabolic Mechanism ◽  
Comprehensive Metabolomics

Abstract PP242, an inhibitor of mechanistic target of rapamycin (mTOR), displays potent anticancer effects against various cancer types. However, the underlying metabolic mechanism associated with the PP242 effects is not clearly understood. In this study, comprehensive metabolomics and lipidomics investigations were performed using ultra-high-performance chromatography-Orbitrap-mass spectrometry (UHPLC-Orbitrap-MS) in plasma and tumor tissue to reveal the metabolic mechanism of PP242 in an LS174T cell-induced colon cancer xenograft mouse model. After 3 weeks of PP242 treatment, a reduction in tumor size and weight was observed without any critical toxicities. According to results, metabolic changes due to the effects of PP242 were not significant in plasma. In contrast, metabolic changes in tumor tissues were very significant in the PP242-treated group compared to the xenograft control (XC) group, and revealed that energy and lipid metabolism were mainly altered by PP242 treatment like other cancer inhibitors. Additionally, in this study, it was discovered that not only TCA cycle but also fatty acid β-oxidation (β-FAO) for energy metabolism was inhibited and clear reduction in glycerophospholipid was observed. This study reveals new insights into the underlying anticancer mechanism of the dual mTOR inhibitor PP242, and could help further to facilitate the understanding of PP242 effects in the clinical application.

scholarly journals {Ru(CO)x}-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo

2017 ◽  
Vol 46 (9) ◽  
pp. 3025-3040 ◽  
Author(s):  
Gabriella Tamasi ◽  
Antonello Merlino ◽  
Federica Scaletti ◽  
Petra Heffeter ◽  
Anton A. Legin ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Anticancer Activity ◽  
Antitumor Effects ◽  
X Ray ◽  
Murine Colon

fac-[RuII(CO)3Cl2(MBI)] and -[RuII(CO)3Cl2(DMBI)] are CO-releasing materials able to link histidines of proteins, and the latter showed antitumor effects in murine colon cancer.

Combinatorial therapy using RNAi and curcumin nano-architectures regresses tumors in breast and colon cancer models

Nanoscale ◽  
2022 ◽  
Author(s):  
Aviral Kumar ◽  
Amarnath Singam ◽  
Guruprasadh Swaminathan ◽  
Naresh Killi ◽  
Naveen Kumar Tangudu ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Colorectal Cancers ◽  
Murine Models ◽  
Combinatorial Therapy ◽  
Cancer Models ◽  
S 100 ◽  
Eudragit S 100

This novel combination of curcumin (CU)–chitosan (CS) nanocomposites conjugated to Ephb4 shRNA encapsulated with Eudragit S-100 (ES) has been developed to combat breast and colorectal cancers murine models.

Sign in / Sign up

Export Citation Format

Share Document